Clinical Trial Update: A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of SRA737 in advanced solid tumors and non-Hodgkin's lymphoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• Solid Tumors

Drugs mentioned

• SRA737 (SRA737)

Snippet

Sponsor: Sierra Oncology LLC - a GSK company | Conditions: Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-03-10